A systematic review of prion therapeutics in experimental models.
暂无分享,去创建一个
[1] J. Griffith,et al. Nature of the Scrapie Agent: Self-replication and Scrapie , 1967, Nature.
[2] J. Griffith,et al. Self-replication and scrapie. , 1967, Nature.
[3] I. Gresser,et al. An attempt to modify scrapie in mice by the administration of interferon. , 1968, The Journal of general virology.
[4] D. Haig,et al. The effect of beta-propiolactone on the scrapie agent. , 1968, The Journal of general virology.
[5] E. J. Field,et al. Failure of interferon to modify scrapie in the mouse. , 1969, The Journal of general virology.
[6] H. Fraser,et al. Pathogenesis of Scrapie in the Mouse: the Role of the Spleen , 1970, Nature.
[7] M. Raff,et al. Scrapie in Immunologically Deficient Mice , 1971, Nature.
[8] M. Worthington,et al. Lack of effect of immunosuppression on scrapie infection in mice. , 1971, The Journal of general virology.
[9] K. W. Cochran. Failure of adenine arabinoside to modify scrapie in mice. , 1971, The Journal of general virology.
[10] H. Fraser,et al. Scrapie: Effect of Dh gene on incubation period of extraneurally injected agent , 1972, Heredity.
[11] M. Worthington. Interferon System in Mice Infected with the Scrapie Agent , 1972, Infection and immunity.
[12] H. Fraser,et al. Developmental Maturation of Susceptibility to Scrapie in Mice , 1973, Nature.
[13] D. Porter,et al. Failure to demonstrate a humoral immune response to scrapie infection in mice. , 1973, Journal of immunology.
[14] H. Fraser,et al. Reduced susceptibility to scrapie in mice after steroid administration , 1974, Nature.
[15] H. Fraser,et al. SLOW ENCEPHALOPATHIES, INFLAMMATORY RESPONSES, AND ARACHIS OIL , 1975, The Lancet.
[16] L. B. Allen,et al. ACCELERATION OF SCRAPIE IN MICE BY TARGET‐ORGAN TREATMENT WITH INTERFERON INDUCERS , 1977, Annals of the New York Academy of Sciences.
[17] M. Ravid,et al. EFFECT OF A SINGLE DOSE OF DIMETHYL SULPHOXIDE ON RENAL AMYLOIDOSIS , 1977, The Lancet.
[18] H. Fraser,et al. Studies of the lymphoreticular system in the pathogenesis of scrapie: the role of spleen and thymus. , 1978, Journal of comparative pathology.
[19] P. Burge. COLOPHONY AND ASTHMA , 1979, The Lancet.
[20] R. Kimberlin,et al. ANTIVIRAL COMPOUND EFFECTIVE AGAINST EXPERIMENTAL SCRAPIE , 1979, The Lancet.
[21] J. Tateishi,et al. Antibiotics and antivirals do not modify experimentally-induced Creutzfeldt-Jakob disease in mice , 1981, Journal of neurology, neurosurgery, and psychiatry.
[22] A. Woody,et al. Spectroscopic studies of Congo Red binding to RNA polymerase. , 1981, Biochimica et biophysica acta.
[23] M. Ravid,et al. Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis. , 1982, Annals of the rheumatic diseases.
[24] S. Prusiner,et al. Identification of a protein that purifies with the scrapie prion. , 1982, Science.
[25] S. Prusiner. Novel proteinaceous infectious particles cause scrapie. , 1982, Science.
[26] R. L. Chandler,et al. Failure to modify scrapie in mice by administration of interferon or anti-interferon globulin. , 1983, The Journal of general virology.
[27] S. Prusiner,et al. Antibodies to a scrapie prion protein , 1984, Nature.
[28] H. Diringer,et al. The reticuloendothelial system in scrapie pathogenesis. , 1984, The Journal of general virology.
[29] V. M. Roikhel',et al. Influence of aminasine on experimental scrapie in mice. , 1984, Acta virologica.
[30] Roĭkhel' Vm,et al. Influence of aminasine on experimental scrapie in mice. , 1984 .
[31] R. Kimberlin,et al. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions , 1986, Antimicrobial Agents and Chemotherapy.
[32] A. Dickinson,et al. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. , 1986, The Journal of general virology.
[33] H. Wiśniewski,et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins , 1987, Journal of virology.
[34] C. Masullo,et al. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. , 1987, The Journal of general virology.
[35] S. Prusiner,et al. Immunoaffinity purification and neutralization of scrapie prion infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[36] P. Casaccia,et al. Amphotericin B: a novel class of antiscrapie drugs. , 1989, The Journal of infectious diseases.
[37] S. Prusiner,et al. Spontaneous neurodegeneration in transgenic mice with mutant prion protein , 1990, Science.
[38] S. Prusiner,et al. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells , 1990, The Journal of cell biology.
[39] G. J. Raymond,et al. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. , 1991, The Journal of biological chemistry.
[40] B. Ehlers,et al. Chemoprophylaxis of scrapie in mice. , 1991, The Journal of general virology.
[41] M. Pocchiari,et al. Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation , 1992, Nature.
[42] B. Fitzgerald,et al. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. , 1992, The Journal of biological chemistry.
[43] B. Caughey,et al. Potent Inhibition of Scrapie‐Associated PrP Accumulation by Congo Red , 1992, Journal of neurochemistry.
[44] H. Fraser,et al. The basis of strain variation in scrapie. , 1992 .
[45] M. Salvatore,et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. , 1992, The Journal of general virology.
[46] B. Caughey,et al. Congo red inhibition of scrapie agent replication , 1993, Journal of virology.
[47] S. Prusiner,et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[48] A. Aguzzi,et al. Mice devoid of PrP are resistant to scrapie , 1993, Cell.
[49] G. J. Raymond,et al. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells , 1993, Journal of virology.
[50] S. Ben‐Sasson,et al. Heparin‐like molecules bind differentially to prion‐proteins and change their intracellular metabolic fate , 1993, Journal of cellular physiology.
[51] H. Ushijima,et al. Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. , 1993, European journal of pharmacology.
[52] G. J. Raymond,et al. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red [corrected] , 1994, Journal of virology.
[53] G. Forloni,et al. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. , 1994, The Journal of biological chemistry.
[54] Binding of the Protease-Sensitive Form of PrP (Prion Protein) to Sulfated Glycosaminoglycan and Congo Red , 1994 .
[55] A. Aguzzi,et al. No propagation of prions in mice devoid of PrP , 1994, Cell.
[56] B. Caughey,et al. Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis. , 1994, Molecular neurobiology.
[57] W. Ee. Women of courage: commercial sex workers mobilize for HIV / AIDS prevention in Nigeria. , 1994 .
[58] D. Dormont,et al. Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. , 1994, The Journal of general virology.
[59] A. Aguzzi,et al. High Prion and PrPSc Levels but Delayed Onset of Disease in Scrapie-Inoculated Mice Heterozygous for a Disrupted PrP Gene , 1994, Molecular medicine.
[60] J. Aiken,et al. Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection , 1994, Journal of virology.
[61] R. Marsh,et al. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy , 1994, Journal of virology.
[62] J. Pettegrew,et al. Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease , 1994, Neurobiology of Aging.
[63] D. Dormont,et al. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie , 1995, Antimicrobial agents and chemotherapy.
[64] P. Lantos,et al. Transmission of fatal familial insomnia to laboratory animals , 1995, The Lancet.
[65] K. Moulder,et al. Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.
[66] L. Gianni,et al. New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. , 1995, Blood.
[67] E. Arbustini,et al. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[68] M. Pocchiari,et al. Congo red prolongs the incubation period in scrapie-infected hamsters , 1995, Journal of virology.
[69] F. Cohen,et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein , 1995, Cell.
[70] J.. Neurodegenerative Diseases , 1996, GWUMC Department of Biochemistry and Molecular Biology Annual Spring Symposia.
[71] Andrew F. Hill,et al. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD , 1996, Nature.
[72] A. Hofman,et al. A new variant of Creutzfeldt-Jakob disease in the UK , 1996, The Lancet.
[73] D. Dormont,et al. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. , 1996, Research in virology.
[74] S. Prusiner,et al. Chemical chaperones interfere with the formation of scrapie prion protein. , 1996, The EMBO journal.
[75] M. Groschup,et al. Generation of Monoclonal Antibodies against Human Prion Proteins in PrP0/0 Mice , 1996, Molecular medicine.
[76] S. Prusiner,et al. Evidence for the Conformation of the Pathologic Isoform of the Prion Protein Enciphering and Propagating Prion Diversity , 1996, Science.
[77] M. Smits,et al. PrP genotype contributes to determining survival times of sheep with natural scrapie. , 1996, The Journal of general virology.
[78] D R Burton,et al. Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[79] J. Rossier,et al. Transmission of the BSE Agent to Mice in the Absence of Detectable Abnormal Prion Protein , 1997, Science.
[80] S. Cousens,et al. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent , 1997, Nature.
[81] F. Cohen,et al. COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[82] A. Aguzzi,et al. A crucial role for B cells in neuroinvasive scrapie , 1997, Nature.
[83] R. Riek,et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody , 1997, Nature.
[84] F. Cohen,et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[85] D. Dormont,et al. Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals , 1997, Journal of virology.
[86] Andrew F. Hill,et al. The same prion strain causes vCJD and BSE , 1997, Nature.
[87] G. Forloni,et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. , 1997, Science.
[88] R. Shin,et al. Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease , 1998, The Lancet.
[89] D. Kirsch,et al. Prion Rods Contain Small Amounts of Two Host Sphingolipids as Revealed by Thin-Layer Chromatography and Mass Spectrometry , 1998, Biological chemistry.
[90] J. Pettegrew,et al. Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC12 cells. , 1998, Life sciences.
[91] K. Heeg,et al. Bacterial DNA as immune cell activator. , 1998, Trends in microbiology.
[92] B. Chesebro,et al. Specific Inhibition of in Vitro Formation of Protease-resistant Prion Protein by Synthetic Peptides* , 1998, The Journal of Biological Chemistry.
[93] B. Caughey,et al. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[94] B. Chesebro,et al. Structural Aspects of Congo Red as an Inhibitor of Protease‐Resistant Prion Protein Formation , 1998, Journal of neurochemistry.
[95] Dapsone to delay symptoms in Creutzfeldt-Jakob disease , 1998, The Lancet.
[96] Claudio Soto,et al. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.
[97] R. Gabizon,et al. The Anti-prion Activity of Congo Red , 1998, The Journal of Biological Chemistry.
[98] A. Aguzzi,et al. PrP expression in B lymphocytes is not required for prion neuroinvasion , 1998, Nature Medicine.
[99] P. Eikelenboom,et al. Heparan Sulfate Proteoglycan Is Associated with Amyloid Plaques and Neuroanatomically Targeted PrP Pathology throughout the Incubation Period of Scrapie-Infected Mice , 1998, Experimental Neurology.
[100] H. Fraser,et al. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells , 1999, Nature Medicine.
[101] A. Dickinson,et al. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies , 1999, The Lancet.
[102] D. Dormont,et al. New insight into abnormal prion protein using monoclonal antibodies. , 1999, Biochemical and biophysical research communications.
[103] D. Barritault,et al. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[104] K. Adjou,et al. Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice. , 1999, The Journal of general virology.
[105] J Collinge,et al. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. , 1999, Science.
[106] Z. Meiner,et al. Protease-resistant and Detergent-insoluble Prion Protein Is Not Necessarily Associated with Prion Infectivity* , 1999, The Journal of Biological Chemistry.
[107] B. Chesebro,et al. Species-Independent Inhibition of Abnormal Prion Protein (PrP) Formation by a Peptide Containing a Conserved PrP Sequence , 1999, Journal of Virology.
[108] B. Caughey,et al. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease‐resistant state , 1999, The EMBO journal.
[109] B. Chesebro,et al. Effectiveness of Polyene Antibiotics in Treatment of Transmissible Spongiform Encephalopathy in Transgenic Mice Expressing Syrian Hamster PrP Only in Neurons , 1999, Journal of Virology.
[110] MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. , 1999, The Journal of general virology.
[111] F. Cohen,et al. Elimination of prions by branched polyamines and implications for therapeutics. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[112] B. Caughey,et al. Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation , 2000, Journal of virology.
[113] A. Mangé,et al. Effect of Congo Red on Wild‐Type and Mutated Prion Proteins in Cultured Cells , 2000, Journal of neurochemistry.
[114] T. Wisniewski,et al. Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides , 2000, The Lancet.
[115] M. Pasparakis,et al. Tumor Necrosis Factor Alpha-Deficient, but Not Interleukin-6-Deficient, Mice Resist Peripheral Infection with Scrapie , 2000, Journal of Virology.
[116] P. Lantos,et al. Species-barrier-independent prion replication in apparently resistant species. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[117] K. Winklhofer,et al. Cationic Lipopolyamines Induce Degradation of PrPSc in Scrapie-Infected Mouse Neuroblastoma Cells , 2000, Biological chemistry.
[118] D. Dormont,et al. Pharmacological manipulation of early PrPres accumulation in the spleen of scrapie-infected mice. , 2000, Archives of virology. Supplementum.
[119] J. Hauw,et al. MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters. , 2000, Journal of comparative pathology.
[120] W. Caughey,et al. Porphyrin and phthalocyanine antiscrapie compounds. , 2000, Science.
[121] A. Aguzzi,et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. , 2000, Science.
[122] D. Dormont,et al. Opposite Effects of Dextran Sulfate 500, the Polyene Antibiotic MS-8209, and Congo Red on Accumulation of the Protease-Resistant Isoform of PrP in the Spleens of Mice Inoculated Intraperitoneally with the Scrapie Agent , 2000, Journal of Virology.
[123] F. Cohen,et al. Mimicking dominant negative inhibition of prion replication through structure-based drug design. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[124] G. Forloni,et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. , 2000, Journal of molecular biology.
[125] I. Gilbert,et al. Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. , 2000, The Journal of general virology.
[126] F. Mackay,et al. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie , 2000, Nature Medicine.
[127] B. Chesebro,et al. Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo Red analogs. , 2000, Archives of virology. Supplementum.
[128] A. Mangé,et al. Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures , 2000, Journal of Virology.
[129] M. Walport,et al. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie , 2001, Nature Medicine.
[130] D. Dormont,et al. The 37‐kDa/67‐kDa laminin receptor acts as the cell‐surface receptor for the cellular prion protein , 2001, The EMBO journal.
[131] I. Xenarios,et al. Complement facilitates early prion pathogenesis , 2001, Nature Medicine.
[132] C. Culmsee,et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β‐peptide , 2001 .
[133] D. Riesner,et al. Intracellular re‐routing of prion protein prevents propagation of PrPSc and delays onset of prion disease , 2001, The EMBO journal.
[134] C. Bostock,et al. Scrapie strains maintain biological phenotypes on propagation in a cell line in culture , 2001, The EMBO journal.
[135] G. M. Cole,et al. Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology , 2001, Neurobiology of Aging.
[136] J. Collinge. Prion diseases of humans and animals: their causes and molecular basis. , 2001, Annual review of neuroscience.
[137] F. Heppner,et al. Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies , 2001, Science.
[138] F E Cohen,et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[139] J. Samarut,et al. Efficient Transmission of Two Different Sheep Scrapie Isolates in Transgenic Mice Expressing the Ovine PrP Gene , 2001, Journal of Virology.
[140] S. Prusiner,et al. Shattuck lecture--neurodegenerative diseases and prions. , 2001, The New England journal of medicine.
[141] Y. Cordeiro,et al. DNA Converts Cellular Prion Protein into the β-Sheet Conformation and Inhibits Prion Peptide Aggregation* , 2001, The Journal of Biological Chemistry.
[142] G. Cole,et al. The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse , 2001, The Journal of Neuroscience.
[143] V. Perry,et al. Early behavioural changes in scrapie‐affected mice and the influence of dapsone , 2001, The European journal of neuroscience.
[144] D. Dormont,et al. Identification of interaction domains of the prion protein with its 37‐kDa/67‐kDa laminin receptor , 2001, The EMBO journal.
[145] M. Enari,et al. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[146] M. Beal,et al. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders , 2001, Annals of neurology.
[147] F. Cohen,et al. Branched Polyamines Cure Prion-Infected Neuroblastoma Cells , 2001, Journal of Virology.
[148] J. Collinge,et al. Location and properties of metal-binding sites on the human prion protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[149] I. Cohen,et al. Modulation of proteinase‐K resistant prion protein by prion peptide immunization , 2001, European journal of immunology.
[150] Pauline M. Rudd,et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity , 2001, Nature.
[151] B. Chesebro,et al. Sulfated glycans and elevated temperature stimulate PrPSc‐dependent cell‐free formation of protease‐resistant prion protein , 2001, The EMBO journal.
[152] F. Cohen,et al. Dominant-negative inhibition of prion replication in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[153] S. Ratté,et al. Post‐natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration , 2002, The EMBO journal.
[154] J. Grassi,et al. Filipin Prevents Pathological Prion Protein Accumulation by Reducing Endocytosis and Inducing Cellular PrP Release* , 2002, The Journal of Biological Chemistry.
[155] E. Sigurdsson,et al. Immunization delays the onset of prion disease in mice. , 2002, The American journal of pathology.
[156] H. Kretzschmar,et al. Postexposure prophylaxis against prion disease with a stimulator of innate immunity , 2002, The Lancet.
[157] C. Masters,et al. Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model , 2002, Annals of neurology.
[158] Alun Williams,et al. Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro , 2002, Neuroreport.
[159] J. Ávila,et al. Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases , 2002, Peptides.
[160] M. Famulok,et al. Prion‐Protein‐Specific Aptamer Reduces PrPSc Formation , 2002, Chembiochem : a European journal of chemical biology.
[161] N. Mabbott,et al. Temporary Blockade of the Tumor Necrosis Factor Receptor Signaling Pathway Impedes the Spread of Scrapie to the Brain , 2002, Journal of Virology.
[162] G. Forloni,et al. Tetracyclines affect prion infectivity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[163] S. Prusiner,et al. Cholesterol Depletion and Modification of COOH-Terminal Targeting Sequence of the Priori Protein Inhibit Formation of the Scrapie Isoform , 2002 .
[164] A. Aguzzi,et al. Soluble Dimeric Prion Protein Binds PrPSc In Vivo and Antagonizes Prion Disease , 2003, Cell.
[165] E. Sigurdsson,et al. Copper Chelation Delays the Onset of Prion Disease* , 2003, Journal of Biological Chemistry.
[166] Sebastian Brandner,et al. Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis , 2003, Science.
[167] J. Collinge,et al. Regional heterogeneity of cellular prion protein isoforms in the mouse brain. , 2003, Brain : a journal of neurology.
[168] L. Meijer,et al. Isolation of drugs active against mammalian prions using a yeast-based screening assay , 2003, Nature Biotechnology.
[169] F. Cohen,et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[170] R. Gabizon,et al. Dimethyl sulfoxide delays PrPsc accumulation and disease symptoms in prion-infected hamsters , 2003, Brain Research.
[171] W. Caughey,et al. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. , 2003, The Journal of infectious diseases.
[172] Tomoya Kinumi,et al. Effects of beta-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP(81-145). , 2003, Organic & biomolecular chemistry.
[173] I. Mcconnell,et al. Follicular Dendritic Cell Dedifferentiation by Treatment with an Inhibitor of the Lymphotoxin Pathway Dramatically Reduces Scrapie Susceptibility , 2003, Journal of Virology.
[174] E. Sigurdsson,et al. Anti-prion antibodies for prophylaxis following prion exposure in mice , 2003, Neuroscience Letters.
[175] D. Harris. Trafficking, turnover and membrane topology of PrP. , 2003, British medical bulletin.
[176] P. Henklein,et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent , 2003, Neuroscience Letters.
[177] C. Leucht,et al. The 37 kDa/67 kDa laminin receptor is required for PrPSc propagation in scrapie‐infected neuronal cells , 2003, EMBO reports.
[178] M. Salmona,et al. In vitro Evaluation of the Anti-prionic Activity of Newly Synthesized Congo Red Derivatives , 2003, Arzneimittelforschung.
[179] R. Gabizon,et al. Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. , 2003, Biochemical and biophysical research communications.
[180] J. Collinge,et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease , 2003, Nature.
[181] S. Mohri,et al. Generation of antibodies against prion protein by scrapie-infected cell immunization of PrP(0/0) mice. , 2003, Hybridoma and hybridomics.
[182] F. Heppner,et al. Immune system and peripheral nerves in propagation of prions to CNS. , 2003, British medical bulletin.
[183] J. Hope,et al. Characterization of 2′-Fluoro-RNA Aptamers That Bind Preferentially to Disease-associated Conformations of Prion Protein and Inhibit Conversion* , 2003, Journal of Biological Chemistry.
[184] T. Ben-Hur,et al. Copper binding to PrPC may inhibit prion disease propagation , 2003, Brain Research.
[185] G. Forloni,et al. Evaluation of Quinacrine Treatment for Prion Diseases , 2003, Journal of Virology.
[186] S. Supattapone,et al. In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. , 2003, Biochemistry.
[187] J. Chabry,et al. Specific inhibition of pathological prion protein accumulation by small interfering RNAs , 2003, Journal of Cell Science.
[188] D. Dormont,et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. , 2003, The Journal of general virology.
[189] I. Gilbert,et al. In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion. , 2003, The Journal of general virology.
[190] E. Wolf,et al. Polyclonal Anti-PrP Auto-antibodies Induced with Dimeric PrP Interfere Efficiently with PrPSc Propagation in Prion-infected Cells* , 2003, The Journal of Biological Chemistry.
[191] G. J. Raymond,et al. Inhibition of Protease-Resistant Prion Protein Accumulation In Vitro by Curcumin , 2003, Journal of Virology.
[192] S. Prusiner,et al. Differential Inhibition of Prion Propagation by Enantiomers of Quinacrine , 2003, Laboratory Investigation.
[193] J. Chapuis,et al. Efficient and specific down-regulation of prion protein expression by RNAi. , 2003, Biochemical and biophysical research communications.
[194] I. Cohen,et al. Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice , 2003, Journal of neuroscience research.
[195] B. Caughey,et al. New Inhibitors of Scrapie-Associated Prion Protein Formation in a Library of 2,000 Drugs and Natural Products , 2003, Journal of Virology.
[196] S. Akira,et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.
[197] J. Solassol,et al. Anti‐PrP antibodies block PrPSc replication in prion‐infected cell cultures by accelerating PrPC degradation , 2004, Journal of neurochemistry.
[198] S. Prusiner,et al. Sulfated glycosaminoglycans in amyloid plaques of prion diseases , 2004, Acta Neuropathologica.
[199] J. Solassol,et al. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. , 2004, The Journal of general virology.
[200] N. Ishiguro,et al. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. , 2004, The Journal of general virology.
[201] J. Ironside,et al. Variant Creutzfeldt-Jakob disease. , 2004, Folia neuropathologica.
[202] N. Ishiguro,et al. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. , 2004, Virology.
[203] P. Mantegazza,et al. Evaluation of Anti-Prion Activity of Congo Red and its Derivatives in Experimentally Infected Hamsters , 2004, Arzneimittelforschung.
[204] M. Head,et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004, The Lancet.
[205] B. Caughey,et al. Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. , 2004, The Journal of general virology.
[206] Alun Williams,et al. Phospholipase A2 Inhibitors or Platelet-activating Factor Antagonists Prevent Prion Replication* , 2004, Journal of Biological Chemistry.
[207] Jun-ichi Kira,et al. Quinoline Derivatives Are Therapeutic Candidates for Transmissible Spongiform Encephalopathies , 2004, Journal of Virology.
[208] Y. Kuroiwa,et al. Non-glycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrPSc replication in vitro , 2004, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[209] M. Salmona,et al. Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity* , 2004, Journal of Biological Chemistry.
[210] J. Collinge,et al. PrPSc Binding Antibodies Are Potent Inhibitors of Prion Replication in Cell Lines* , 2004, Journal of Biological Chemistry.
[211] G. Millhauser. Copper binding in the prion protein. , 2004, Accounts of chemical research.
[212] Mark Head,et al. Preclinical variant CJD after blood transfusion in a PRNP codon 129 heterozygous patient , 2004 .
[213] J Mackenzie,et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion , 2004, The Lancet.
[214] I. Gilbert,et al. Synthesis of analogues of Congo red and evaluation of their anti-prion activity. , 2004, Journal of medicinal chemistry.
[215] T. Iwaki,et al. Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal Models , 2004, Journal of Virology.
[216] Seong-Wook Yun,et al. The Tyrosine Kinase Inhibitor STI571 Induces Cellular Clearance of PrPSc in Prion-infected Cells* , 2004, Journal of Biological Chemistry.
[217] S. Lehmann,et al. Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations , 2004, Journal of Cell Science.
[218] J. Collinge,et al. Protein Conformation Significantly Influences Immune Responses to Prion Protein1 , 2005, The Journal of Immunology.
[219] T. Yokoyama,et al. Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein. , 2005, Biochemical and biophysical research communications.
[220] B. Lucchini,et al. Evaluation of Anti-Prionic Activity of Clioquinol in an in vivo Model (Mesocricetus auratus) , 2005, Veterinary Research Communications.
[221] P. Tavan,et al. Systematic Identification of Antiprion Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent Targets , 2005, Journal of Virology.
[222] A. Domb,et al. Cationic polysaccharides as antiprion agents. , 2005, Journal of medicinal chemistry.
[223] E. Sigurdsson,et al. Mucosal vaccination delays or prevents prion infection via an oral route , 2005, Neuroscience.
[224] S. Simon,et al. Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells* , 2005, Journal of Biological Chemistry.
[225] R. Kimberlin,et al. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection , 2005, Archives of Virology.
[226] M. Groschup,et al. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication , 2005, Journal of Cell Science.
[227] S. Biocca,et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. , 2005, Biochemical and biophysical research communications.
[228] S. Supattapone,et al. Protease-resistant Prion Protein Amplification Reconstituted with Partially Purified Substrates and Synthetic Polyanions* , 2005, Journal of Biological Chemistry.
[229] N. Greig,et al. Inhibition of P53-related apoptosis had no effect on PrPSc accumulation and prion disease incubation time , 2005, Neurobiology of Disease.
[230] F. Heppner,et al. Paracrine Inhibition of Prion Propagation by Anti-PrP Single-Chain Fv Miniantibodies , 2005, Journal of Virology.
[231] John Collinge,et al. Rational targeting for prion therapeutics , 2005, Nature Reviews Neuroscience.
[232] B. Caughey,et al. Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie , 2005, Neuroscience Letters.
[233] S. Biocca,et al. Trapping Prion Protein in the Endoplasmic Reticulum Impairs PrPC Maturation and Prevents PrPSc Accumulation* , 2005, Journal of Biological Chemistry.
[234] K. Kristensson,et al. Inhibitors of the Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Pathway Clear Prion-Infected Cells from PrPSc , 2005, The Journal of Neuroscience.
[235] M. Clerici,et al. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. , 2005, Vaccine.
[236] N. Mabbott,et al. Follicular dendritic cell dedifferentiation reduces scrapie susceptibility following inoculation via the skin , 2005, Immunology.
[237] B. Caughey,et al. Potent Antiscrapie Activities of Degenerate Phosphorothioate Oligonucleotides , 2006, Antimicrobial Agents and Chemotherapy.
[238] B. Caughey,et al. Mefloquine, an Antimalaria Drug with Antiprion Activity In Vitro, Lacks Activity In Vivo , 2006, Journal of Virology.
[239] V. Gillet,et al. Library design, synthesis, and screening: pyridine dicarbonitriles as potential prion disease therapeutics. , 2006, Journal of medicinal chemistry.
[240] S. Supattapone,et al. Copper (II) ions potently inhibit purified PrPres amplification , 2006, Journal of neurochemistry.
[241] G. J. Raymond,et al. Inhibition of Protease-Resistant Prion Protein Formation in a Transformed Deer Cell Line Infected with Chronic Wasting Disease , 2006, Journal of Virology.
[242] B. Caughey,et al. A Porphyrin Increases Survival Time of Mice after Intracerebral Prion Infection , 2006, Antimicrobial Agents and Chemotherapy.
[243] D. Berlin,et al. Dextran Sulphate 500 Delays and Prevents Mouse Scrapie by Impairment of Agent Replication in Spleen , 2007 .